|
Daily Medical Update
Hypertriglyceridemia
Monday, May 25, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The New England journal of medicine (2025) - Phase III RCT
Key Findings
- At 6 months, placebo-adjusted triglyceride change was -58.4 percentage points with olezarsen 50 mg and -60.6 percentage points with olezarsen 80 mg versus placebo (P<0.001 for both).
- Serious adverse event rates were similar across trial groups despite large triglyceride reductions in statin-treated, high-cardiovascular-risk patients.
📋 Practice Implication: For adults with triglycerides 150 to 499 mg/dL and elevated cardiovascular risk despite standard therapy, olezarsen now has phase 3 evidence to justify adding targeted triglyceride-lowering treatment.
|
The New England journal of medicine (2025) - Phase III RCT
Key Findings
- Across two phase 3 trials, placebo-adjusted triglyceride reduction at 6 months ranged from -49.2 to -72.2 percentage points with monthly olezarsen, with P<0.001 for all dose comparisons.
- Acute pancreatitis incidence was lower with olezarsen than placebo (mean rate ratio 0.15; 95% CI 0.05 to 0.40; P<0.001), although liver-enzyme elevations and thrombocytopenia were more common with 80 mg.
📋 Practice Implication: In severe hypertriglyceridemia, olezarsen can be used not just to lower triglycerides but to reduce pancreatitis events, with dose selection and laboratory monitoring shaped by the higher-risk 80 mg profile.
|
Alimentary pharmacology & therapeutics (2026) - Phase III RCT
Key Findings
- Median triglycerides fell by more than 75% with plozasiran, and median levels dropped below 5.65 mmol/L (500 mg/dL) in participants with prior pancreatitis.
- Recurrent acute pancreatitis risk fell by 83% versus placebo (HR 0.17; 95% CI 0.03 to 0.87; p < 0.017), with lower hospitalization burden and shorter length of stay.
📋 Practice Implication: For patients with very severe hypertriglyceridemia or familial chylomicronemia syndrome and prior pancreatitis, plozasiran has direct randomized evidence for secondary pancreatitis prevention.
|
Diabetes, obesity & metabolism (2026) - Meta-Analysis
Key Findings
- Across 15 RCTs with 3934 patients, all ApoC-III inhibitors except volanesorsen 100 mg weekly and olezarsen 10 mg every 4 weeks significantly reduced triglycerides.
- Olezarsen 80 mg every 4 weeks had the top triglyceride-lowering ranking (MD -63.26; 95% CI -70.04 to -56.47; p < 0.01), and the class lowered pancreatitis incidence (HR 0.16; 95% CI 0.07 to 0.33; p < 0.01) without increasing serious adverse events.
📋 Practice Implication: When selecting an ApoC-III agent, current comparative evidence supports treating this as a dose-sensitive class effect and places olezarsen 80 mg monthly as the strongest triglyceride-lowering benchmark.
|
Endocrinology, diabetes & metabolism (2026) - Meta-Analysis
Key Findings
- In 4 RCTs involving 1615 high-risk patients, olezarsen reduced triglycerides by 47.71%, non-HDL-C by 22.11%, ApoC-III by 68.93%, VLDL-C by 48.52%, and ApoB by 10.67% versus placebo (p <= 0.0007 for each).
- Acute pancreatitis events were fewer with olezarsen (p = 0.035), while liver enzyme elevations at least 3 times the upper limit of normal were more frequent (p = 0.046) and serious adverse events were otherwise comparable to placebo.
📋 Practice Implication: In persistent hypertriglyceridemia with high cardiovascular risk, olezarsen has higher-certainty adjunct evidence, but follow-up should explicitly include hepatic safety monitoring rather than focusing only on lipid response.
|
|
💡
Summary
Recent hypertriglyceridemia evidence is dominated by ApoC-III targeting therapies, with consistent triglyceride reductions of roughly 50% to 70% and lower pancreatitis event rates across moderate, severe, and very severe disease. Olezarsen has the most mature phase 3 and meta-analytic data, while plozasiran adds prospective randomized evidence for recurrent pancreatitis prevention in patients with very severe hypertriglyceridemia.
|
|